Characteristics of the study and historical control groups
. | No. (%) . | . | . | ||
|---|---|---|---|---|---|
| Parameter . | Study group . | Historical group . | P . | ||
| Age, 60 y or older [median age, y] | 31 (27)[48] | 13 (26)[48] | 1.0 | ||
| Female sex | 44 (39) | 24 (48) | .34 | ||
| Performance status 2 | 2 (2) | 0 (0) | 1.0 | ||
| Splenomegaly | 31 (27) | 11 (22) | .56 | ||
| Diagnosis to therapy, mo [median time, mo] | [1] | [2] | |||
| 0 | 19 (17) | 5 (10) | .34 | ||
| 1 to 11 | 95 (83) | 45 (90) | |||
| Hemoglobin level [median level, g/L] | [123] | [125] | |||
| Less than 100 g/L | 3 (3) | 3 (6) | .37 | ||
| WBC count, × 109/L [median count, × 109/L] | [32.2] | [22.5] | |||
| 50 or higher | 41 (36) | 11 (22) | .1 | ||
| Platelet count, × 109/L [median count, × 109/L] | [375] | [382] | |||
| 450 to 700 | 27 (24) | 11 (22) | .76 | ||
| Higher than 700 | 18 (16) | 6 (12) | |||
| Peripheral blasts, any | 42 (37) | 14 (28) | .29 | ||
| Peripheral basophils, 7% or more | 29 (25) | 10 (20) | .55 | ||
| Marrow blasts, more than 5% | 6 (5) | 0 (0) | .18 | ||
| Marrow basophils, 5% or more | 26 (23) | 7 (14) | .21 | ||
| Clonal evolution present | 6 (5) | 0 (0) | .18 | ||
| Sokal risk group | .14 | ||||
| Low | 41 (36) | 24 (48) | |||
| Intermediate | 37 (32) | 12 (24) | |||
| High | 21 (18) | 12 (24) | |||
| Unknown | 15 (13) | 2 (4) | |||
. | No. (%) . | . | . | ||
|---|---|---|---|---|---|
| Parameter . | Study group . | Historical group . | P . | ||
| Age, 60 y or older [median age, y] | 31 (27)[48] | 13 (26)[48] | 1.0 | ||
| Female sex | 44 (39) | 24 (48) | .34 | ||
| Performance status 2 | 2 (2) | 0 (0) | 1.0 | ||
| Splenomegaly | 31 (27) | 11 (22) | .56 | ||
| Diagnosis to therapy, mo [median time, mo] | [1] | [2] | |||
| 0 | 19 (17) | 5 (10) | .34 | ||
| 1 to 11 | 95 (83) | 45 (90) | |||
| Hemoglobin level [median level, g/L] | [123] | [125] | |||
| Less than 100 g/L | 3 (3) | 3 (6) | .37 | ||
| WBC count, × 109/L [median count, × 109/L] | [32.2] | [22.5] | |||
| 50 or higher | 41 (36) | 11 (22) | .1 | ||
| Platelet count, × 109/L [median count, × 109/L] | [375] | [382] | |||
| 450 to 700 | 27 (24) | 11 (22) | .76 | ||
| Higher than 700 | 18 (16) | 6 (12) | |||
| Peripheral blasts, any | 42 (37) | 14 (28) | .29 | ||
| Peripheral basophils, 7% or more | 29 (25) | 10 (20) | .55 | ||
| Marrow blasts, more than 5% | 6 (5) | 0 (0) | .18 | ||
| Marrow basophils, 5% or more | 26 (23) | 7 (14) | .21 | ||
| Clonal evolution present | 6 (5) | 0 (0) | .18 | ||
| Sokal risk group | .14 | ||||
| Low | 41 (36) | 24 (48) | |||
| Intermediate | 37 (32) | 12 (24) | |||
| High | 21 (18) | 12 (24) | |||
| Unknown | 15 (13) | 2 (4) | |||
Populations are as follows: study group, N = 114; historical group, N = 50.